國家衛生研究院 NHRI:Item 3990099045/5752
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 907511      在线人数 : 955
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/5752


    题名: Novel Hsp90 inhibitor NVP-AUY922 downregulates mutant c-Kit protein through transcription and enhancing protein degradation via both proteasome and autophagy-mediated pathways
    作者: Hsueh, YS;Chiang, NJ;Yen, CC;Shih, NY;Chen, LT
    贡献者: National Institute of Cancer Research
    摘要: Background: Gastrointestinal stromal tumors (GISTs) mostly harbor oncogenic c-Kit mutations or, partially, with plate-let-derived growth factor receptor alpha (PDGFRA). Imatinib (Gleevec?; Novartis Pharmaceuticals Corporation, East hanover, New Jersey, USA) is a selective tyrosine kinase inhibitor (TKI) achieving a partial response or stable disease in nearly 80% of patients with metastatic GIST. However, imatinib resistance is an increasing clinical problem during chronic therapy due to secondary mutation of c-Kit, most on exons 13, 14, or 17. Several TKIs and universal inhibitors are studied to overcome imatinib-resistance. Hsp90 inhibitor was proven that it could inhibit c-Kit protein expression on several GIST cell lines, but double mutants of c-Kit that led to drug-resistance were not well-con rmed. Moreover, the mechanism of Hsp90 related c-Kit inhibition is not clari ed. Method: COS-1 cells transfected with mutated c-Kit protein and c-Kit endogenous GIST882 cells were used to validate a novel Hsp90 inhibitor, NVP-AUY922, e cacies on imatinib-sensitive and -resistant c-Kit mutants. Detail mechanisms of protein regulation, as RNA transcription, RNA stability, and protein degradation, were studied. Results: NVP-AUY922, the most potent Hsp90 inhibitor recently studied, inhibited the proliferation of imatinib-sensitive GIST882 cells and induced apoptosis. NVP-AUY922 also downregulated both total and phosphorylated c-Kit proteins in dose- and time-dependent manners in GIST882 cells. e COS-1 cells expressed c-Kit protein, acquiring single mutants on exon11 or 17 or imatinib-resistant double mutants on exon11/17, were also suppressed by NVP-AUY922. In addition, c-Kit RNA was reduced under NVP-AUY922 treatment on GIST882 cells through gene transcription, but not on the COS-1 cell model, which could be explained by the use of cytomegalovirus promoter in the arti cial COS-1 cell model. Further studies on the protein-degradation pathway indicated that proteosome and autophagy both played roles in NVP-AUY922–induced c-Kit inhibition on GIST882 and COS-1 cells. e involvement of autophagy in NVP-AUY922–induced c-Kit protein degradation was further con rmed by LC3 conversion and colocalization of c-Kit with autophagosome by immunostaining. Conclusion: Taken together, NVP-AUY922 could inhibit c-Kit expression, despite imatinib-sensitive and -resistant mutations. Our ndings rst proved that both transcription and autophagy were involved in NVP-AUY922–induced mutant c-Kit protein downregulation. ese observations highlight the use of NVP-AUY922 in imatinib-refractory, c-Kit-expressing GIST.
    日期: 2011-05
    關聯: Drug Metabolism Reviews. 2011 May;43(Suppl. 1):78-79.
    Link to: http://dx.doi.org/10.3109/03602532.2011.567811
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0360-2532&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000289629400144
    显示于类别:[陳立宗] 會議論文/會議摘要
    [施能耀] 會議論文/會議摘要
    [姜乃榕] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000289629400144.pdf1157KbAdobe PDF709检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈